Challenge Roivant’s business model involves evaluating therapies across all therapeutic areas, modalities, and stages for potential acquisition or in-licensing and then creating and governing subsidiary companies around those therapies. At any given time, Roivant has dozens of projects up and running that require deep research and analysis. For Sandeep Kulkarni, VP of Special Projects at Roivant, an MD by training and former public market biotech investor, evaluating potential business combinations and diligencing new investment opportunities was largely a piecemeal and low-tech process, involving a lot of searching on EDGAR and Yahoo Finance. Solution Roivant chose the Sentieo Financial and Corporate Research Platform to serve as an intuitive aggregator for all of the cont

Join for free to read